Simulect (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Simulect drug offered from Novartis Pharmaceuticals Corporation. This Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | basiliximab |
SUBSTANCE NAME: | BASILIXIMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, FOR SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 1998-05-12 |
END MARKETING DATE: | 0000-00-00 |
Simulect HUMAN PRESCRIPTION DRUG Details:
Item Description | Simulect from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 10(mg/2.5mL) |
START MARKETING DATE: | 1998-05-12 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0393_88e1d8f7-be69-4d69-b417-0125a8a6b4b9 |
PRODUCT NDC: | 0078-0393 |
APPLICATION NUMBER: | BLA103764 |
Other BASILIXIMAB Pharmaceutical Manufacturers / Labelers: